Home › Myeloproliferative Neoplasms › NCT05842603
I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
Recruiting
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: -≥18 years of age * Diagnosed with an MPN by WHO 2016 criteria,22 including essential thrombocythemia (ET), polycythemia vera (PV), prefibrotic myelofibrosis (pre-MF), myelofibrosis (MF), and MPN not otherwise specified (NOS). Within MF patients, only patients who are low or intermediate-1 risk by the Dynamic International Prognostic Scoring System (DIPSS) are eligible.23 All risk groups are eligible for the remaining MPN subtypes. * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Must have at least one cardiovascular risk factor including: Body mass index (BMI) \>25 kg/m2, hypertension, hyperlipidemia, diabetes mellitus or pre-diabetes or metabolic syndrome, or any prior history of cardiovascular disease, transient ischemic attack, stroke, or peripheral vascular disease. Patients not meeting any cardiovascular risk criteria must receive prior approval from the PI to participate in this study. Exclusion Criteria: \-- MF patients with intermediate-2 or high-risk disease by DIPSS * ECOG performance status \>2. * Any injury or medical condition that would prohibit being able to safely perform exercise, as determined by the treating physician.
About the study
The goal of this study is to see if patients with myeloproliferative disorders are able to successfully complete the Cardiac Lifestyle Program(CLP). The goal of the CLP is to teach patients how to become more active and eat healthier foods.
The name of the intervention used in this research study is:
Cardiac Lifestyle Program (a 12-week, tailored nutrition and physical activity program)
What is being tested
- Cardiac Lifestyle Program (behavioral)
Sponsor: Massachusetts General Hospital · Participants: 30 · Started: Mar 1, 2024
Contact the study team
- Gabriela Hobbs, MD · Phone: 617-724-1124
- Gabriella Hobbs, MD · Phone: 617-724-1124
Official record on ClinicalTrials.gov — NCT05842603
Locations in the U.S.
| Massachusetts | Brigham and Women's Hospital, Boston Dana-Farber Cancer Institute, Boston (Not yet recruiting) Massachusetts General Hospital Cancer Center, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.